产品
编 号：F174083
分子式：C27H37ClN2O5
分子量：505.05
分子式：C27H37ClN2O5
分子量：505.05
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
100
In-stock
5mg
175
In-stock
10mg
280
In-stock
50mg
600
In-stock
100mg
880
In-stock
200mg
1320
In-stock
结构图
CAS No: 148849-67-6
产品详情
生物活性：
Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity.
体内研究：
Ivabradine hydrochloride (1, 10, 20 mg/kg; i.p.) shows anticonvulsant and neuroprotective action in mice.Ivabradine hydrochloride (5, 10, 20 mg/kg;p.o.; daily for 1 weeks) lowers heart rate in mice with enhanced sympathoadrenergic activities.Animal Model:25-30 g, 6 weeks male Swiss mice
Dosage:1, 10, 20 mg/kg
Administration:I.p.; for 3 days
Result:Attenuated PTZ- and PICRO-induced seizures while presented an antioxidant effect in allbrain areas studied, and reduced cleaved caspase-3 expression in the CA1 and DG region of PICRO- and PTZ-treated mice, respectively.
Animal Model:3-4 months transgenic (TG) mice with cardiac-restricted overexpression of b2AR
Dosage:5, 10, 20 mg/kg
Administration:P.o; daily for 1 weeks
Result:Reduced the maximal HR increase in response to the b-agonist isoproterenol, without modifying the response of contractile parameters at 10 mg/kg.
Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity.
体内研究：
Ivabradine hydrochloride (1, 10, 20 mg/kg; i.p.) shows anticonvulsant and neuroprotective action in mice.Ivabradine hydrochloride (5, 10, 20 mg/kg;p.o.; daily for 1 weeks) lowers heart rate in mice with enhanced sympathoadrenergic activities.Animal Model:25-30 g, 6 weeks male Swiss mice
Dosage:1, 10, 20 mg/kg
Administration:I.p.; for 3 days
Result:Attenuated PTZ- and PICRO-induced seizures while presented an antioxidant effect in allbrain areas studied, and reduced cleaved caspase-3 expression in the CA1 and DG region of PICRO- and PTZ-treated mice, respectively.
Animal Model:3-4 months transgenic (TG) mice with cardiac-restricted overexpression of b2AR
Dosage:5, 10, 20 mg/kg
Administration:P.o; daily for 1 weeks
Result:Reduced the maximal HR increase in response to the b-agonist isoproterenol, without modifying the response of contractile parameters at 10 mg/kg.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备